| scholarly article | Q13442814 |
| P50 | author | Christian Kellner | Q51773278 |
| P2093 | author name string | Wolfram Klapper | |
| Andreas Günther | |||
| Philipp Baumann | |||
| Martin Gramatzki | |||
| Renate Burger | |||
| Ralf Schmidmaier | |||
| P2860 | cites work | The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and | Q36052399 |
| TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms | Q37672563 | ||
| Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 | ||
| Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity | Q39259153 | ||
| Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells | Q39443134 | ||
| AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells | Q40224641 | ||
| Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. | Q40267839 | ||
| Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. | Q40361501 | ||
| Analysis of PTEN deletions and mutations in multiple myeloma | Q40383211 | ||
| Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma | Q40524119 | ||
| Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. | Q40569009 | ||
| Downstream effectors of oncogenic ras in multiple myeloma cells | Q40679257 | ||
| Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma | Q40702649 | ||
| Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. | Q40962190 | ||
| Chemical modification of rapamycin: the discovery of SDZ RAD. | Q42540012 | ||
| Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma | Q43761443 | ||
| Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. | Q44123722 | ||
| Immunophenotyping is an independent factor for risk stratification in AML. | Q44419558 | ||
| Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
| Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors | Q45151645 | ||
| Repp86: a new prognostic marker in mantle cell lymphoma. | Q53647104 | ||
| Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. | Q105219584 | ||
| PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase | Q24300915 | ||
| DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival | Q24311448 | ||
| Phosphatidic acid-mediated mitogenic activation of mTOR signaling | Q28208274 | ||
| A mammalian protein targeted by G1-arresting rapamycin-receptor complex | Q28243712 | ||
| Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency | Q28249019 | ||
| The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins | Q28507365 | ||
| Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress | Q29614493 | ||
| Regulation of translation initiation by FRAP/mTOR | Q29620398 | ||
| Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range | Q33341797 | ||
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure | Q33357118 | ||
| In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model | Q33362103 | ||
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
| Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma | Q33383550 | ||
| Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study | Q33394281 | ||
| Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma | Q33410761 | ||
| Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide | Q33414827 | ||
| Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 | ||
| Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization | Q33920766 | ||
| Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients | Q33983816 | ||
| Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. | Q34374071 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. | Q34490880 | ||
| Mammalian TOR: a homeostatic ATP sensor | Q34519173 | ||
| Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies | Q34546358 | ||
| Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors | Q34547487 | ||
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
| Defining the role of TORC1/2 in multiple myeloma | Q35631315 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 541-547 | |
| P577 | publication date | 2015-02-14 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study | |
| P478 | volume | 100 |
| Q48110513 | Bone-Targeted Therapies in Cancer-Induced Bone Disease |
| Q92861907 | DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2 |
| Q41694198 | Emerging drugs and combinations to treat multiple myeloma |
| Q28067598 | Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update |
| Q54239708 | Living donor liver transplantation prior to multiple myeloma treatment in a patient with hepatitis B-associated hepatocellular carcinoma and liver cirrhosis: a case report. |
| Q92772115 | Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management |
| Q64230046 | NVP-BEZ235-induced autophagy as a potential therapeutic approach for multiple myeloma |
| Q41163641 | New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes. |
| Q48263465 | PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. |
| Q88182734 | Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma |
| Q33429430 | TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia |
| Q51170783 | The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. |
| Q92052566 | The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma |
| Q47107700 | VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. |
| Q39113506 | m-TOR inhibitors and their potential role in haematological malignancies |
Search more.